RxDoctor Payments Data

Baylee Johnson

Family · Fayetteville, TNNPI 1780380618

Payments from drug & device makers

$762in general payments, 2019–2025

Across 36 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$229
  • Novo Nordisk$149
  • Astellas Pharma US Inc$91
  • Exact Sciences$77
  • Lilly USA, LLC$47
  • Dynavax Technologies Corporation$46
  • plus $123 from 4 others

What the payments were for

  • Food & beverage$762100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$762 in reported general payments places this provider in the 55th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$38,667
Medicare patients
147
Services billed
1,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$95,362
OzempicSemaglutide47$46,208
JardianceEmpagliflozin31$36,365
EliquisApixaban36$26,933
JanuviaSitagliptin Phosphate20$21,326
TrulicityDulaglutide19$20,461
JanumetSitagliptin Phos/Metformin Hcl12$8,787
Atorvastatin Calcium249$3,999
Omeprazole122$2,496
Potassium Chloride95$2,470
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen133$2,262
Rosuvastatin Calcium109$2,122
Gabapentin125$1,857
Pantoprazole Sodium80$1,625
Albuterol Sulfate HfaAlbuterol Sulfate62$1,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$149$46,20847 claims
Lilly USA, LLCTrulicity$47$20,46119 claims
AbbVieSynthroid$229$1,15511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,706 family providers in Tennessee.

Other family in Fayetteville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →